Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

US biotech major Amgen will invest about $200 million this year in its new technology center in southern India.

With only four litigation hires making Am Law’s top 25 for this year, firms appear to be gearing up for the expected ...

US drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...

US equity indexes traded mixed after midday Monday amid a decline in technology and as investors awaited Nvidia's (NVDA) earnings and the Federal Reserve's preferred inflation data. The Nasdaq ...

Amgen (NASDAQ:AMGN) reportedly plans to invest over $200M in its newly opened technology and innovation center in Hyderabad, ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

US equity indexes traded mixed after midday Monday amid declines in technology and communication services. The Nasdaq Composite fell 0.4% to 19,456.1. The Dow Jones Industrial Average, however, rose 0 ...